SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3474-3480. Prepublished online as a Blood First Edition Paper on January 5, 2006; DOI 10.1182/blood-2005-09-3869. This Article Full Text (PDF) All Versions of this Article: 2005-09-3869v1 107/9/3474    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Garban, F. Articles by Moreau, P. Search for Related Content PubMed PubMed Citation Articles by Garban, F. Articles by Moreau, P. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 27, 2005 Accepted December 20, 2005 Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Frederic Garban, Michel Attal, Mauricette Michallet, Cyrille Hulin, Jean H Bourhis, Ibrahim Yakoub-Agha, Thierry Lamy, Gerald Marit, Frederic Maloisel, Christian Berthou, Mamoun Dib, Denis Caillot, Bernard dePrijck, Nicolas Ketterer, Jean-Luc Harousseau, Jean-Jacques Sotto, and Philippe Moreau* University Hospital, Grenoble, France University Hospital, Toulouse, France University Hospital, Lyon, France University Hospital, Nancy, France Institut Gustave-Roussy, Paris, France University Hospital, Lille, France University Hospital, Rennes, France University Hospital, Bordeaux, France University Hospital, Strasboug, France University Hospital, Brest, France University Hospital, Angers, France University Hospital, Dijon, France University Hospital, Liege, Belgium University Hospital, Lausanne, Switzerland University Hospital, Nantes, France * Corresponding author; email: philippe.moreau{at}chu-nantes.fr. For patients with high-risk (beta-2 microglobulin > 3mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma, the IFM group has initiated in 1999 two specific trials. In both protocols, induction regimen consisted of VAD followed by a first autologous stem cell transplantation (ASCT) prepared by melphalan 200 mg/m2. Patients with an HLA-sibling donor were subsequently treated with a dose-reduced allogeneic stem cell transplantation (IFM99-03 trial), while patients without an HLA-sibling donor were randomized to receive a second ASCT prepared by melphalan 220 mg/m2 dexamethasone +/- anti-IL6 monoclonal antibody (IFM99-04 protocol). 284 patients were prospectively treated and received at least one course of VAD, 65 in the IFM99-03 trial and 219 in the IFM99-04 trial. On an intent-to-treat basis, the overall survival (OS) and the event-free survival (EFS) did not differ significantly in both studies (median 35 and 25 months in the IFM99-03 trial versus 41 and 30 months in the IFM99-04 trial, respectively). With a median follow-up time of 24 months, the EFS of the 166 patients randomized in the tandem ASCT protocol was similar to the EFS of the 46 patients who received the whole IFM99-03 program, median 35 versus 31.7 months, with a trend for a better OS in patients treated with tandem ASCT, median 47.2 versus 35 months, p = .07. In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to a tandem dose-intensified melphalan-based ASCT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: No RIC in high-risk myeloma? Henk Lokhorst Blood 2006 107: 3420-3421. [Full Text] [PDF] This article has been cited by other articles: J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF] A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells Clin. Cancer Res., July 1, 2009; 15(13): 4499 - 4507. [Abstract] [Full Text] [PDF] A. K. Stewart Reduced-intensity allogeneic transplantation for myeloma: reality bites Blood, April 2, 2009; 113(14): 3135 - 3136. [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] J. Blade and L. Rosinol Changing paradigms in the treatment of multiple myeloma Haematologica, February 1, 2009; 94(2): 163 - 166. [Full Text] [PDF] B. Logan, E. Leifer, C. Bredeson, M. Horowitz, M. Ewell, S. Carter, and N. Geller Use of biological assignment in hematopoietic stem cell transplantation clinical trials Clinical Trials, December 1, 2008; 5(6): 607 - 616. [Abstract] [PDF] P. Moreau, F. Garban, M. Attal, M. Michallet, G. Marit, C. Hulin, L. Benboubker, C. Doyen, M. Mohty, I. Yakoub-Agha, et al. Long-Term Follow-up Results of IFM9903 and IFM9904 Trials Comparing Non Myeloablative Allotransplantation with Autologous Transplantation in High-Risk De Novo Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 1126 - 1126. [Abstract] P. Moreau, F. Garban, M. Attal, M. Michallet, G. Marit, C. Hulin, L. Benboubker, C. Doyen, M. Mohty, I. Yakoub-Agha, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma Blood, November 1, 2008; 112(9): 3914 - 3915. [Full Text] [PDF] L. Rosinol, J. A. Perez-Simon, A. Sureda, J. de la Rubia, F. de Arriba, J. J. Lahuerta, J. D. Gonzalez, J. Diaz-Mediavilla, B. Hernandez, J. Garcia-Frade, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma Blood, November 1, 2008; 112(9): 3591 - 3593. [Abstract] [Full Text] [PDF] S. V. Rajkumar Treatment of Myeloma: Cure vs Control Mayo Clin. Proc., October 1, 2008; 83(10): 1142 - 1145. [Full Text] [PDF] G. Gahrton and B. Bjorkstrand Allogeneic transplantation in multiple myeloma Haematologica, September 1, 2008; 93(9): 1295 - 1300. [Full Text] [PDF] F. Ayuk, J. A. Perez-Simon, A. Shimoni, A. Sureda, T. Zabelina, R. Schwerdtfeger, R. Martino, H. G. Sayer, A. Alegre, J.-J. Lahuerta, et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation Haematologica, September 1, 2008; 93(9): 1343 - 1350. [Abstract] [Full Text] [PDF] J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents J. Clin. Oncol., June 1, 2008; 26(16): 2761 - 2766. [Abstract] [Full Text] [PDF] R. A. Kyle and S. V. Rajkumar Multiple myeloma Blood, March 15, 2008; 111(6): 2962 - 2972. [Abstract] [Full Text] [PDF] J. El-Cheikh, M. Michallet, A. Nagler, H. de Lavallade, F. E. Nicolini, A. Shimoni, C. Faucher, M. Sobh, D. Revesz, I. Hardan, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma Haematologica, March 1, 2008; 93(3): 455 - 458. [Abstract] [Full Text] [PDF] W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF] J.-P. Fermand Initial Therapy for Multiple Myeloma: Role of Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 375 - 379. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] F. van Rhee, J. Crowley, B. Barlogie, S. V. Rajkumar, R. A. Kyle, P. Moreau, J.-L. Harousseau, M. Attal, B. Bruno, G. Ciccone, et al. Allografting or Autografting for Myeloma N. Engl. J. Med., June 21, 2007; 356(25): 2646 - 2648. [Full Text] [PDF] M. Cavo Nonmyeloablative allotransplantation for myeloma: light and shade Blood, April 15, 2007; 109(8): 3134 - 3135. [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omede, I. Baldi, et al. A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma N. Engl. J. Med., March 15, 2007; 356(11): 1110 - 1120. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] R. Fonseca Strategies for Risk-Adapted Therapy in Myeloma Hematology, January 1, 2007; 2007(1): 304 - 310. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF] K.-S. Eom, C.-K. Min, S. Lee, Y.-J. Kim, S.-Y. Kim, H.-J. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 432 - 438. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020